Market Size of Oxycodone Drugs Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Oxycodone Drugs Market Analysis
The oxycodone drugs market is expected to witness growth at a CAGR of 5.6% during the forecast period.
The COVID-19 pandemic impacted the studied market significantly. Owing to the disruption in the supply chain around the world, the pandemic invariably affected the availability of a wide range of drugs and medical supplies, which adversely impacted the market growth during the initial phases of the pandemic. However, the use of oxycodone drugs for pain management during the COVID-19 pandemic increased due to its pain-relieving properties. For instance, an article published in NCBI in December 2021 indicated that oxycodone was used as an analgesic due to the minimal immunosuppressive characteristics of the drug, and the use of the drug substantially increased in the United States and Canada during the pandemic. Thus, such widespread use of oxycodone drugs significantly added to the growth of the market during the COVID-19 pandemic. Therefore, the studied market was impacted significantly by the pandemic considerably and it is expected to continue its strong hold over the forecast period.
The major factors attributing to the growth of the market are a rise in the incidence of chronic pain diseases, such as rheumatoid arthritis (RA), cancer, lower back pain, and fibromyalgia.
There is a burden of RA across countries, globally. For instance, according to the 2022 update of the National Rheumatoid Arthritis Society (NRAS), nearly more than 400,000 people in the United Kingdom had RA in 2021 and it is 2 to 3 times more common in women than in men. This burden of RA is creating demand for opioids such as Oxycodone/acetaminophen. These opioids are prescribed to patients at low dosages for the treatment of chronic pain due to RA. These drugs act as a better alternative to non-steroidal anti-inflammatory drugs (NSAIDs). Thus, this prevalence of several diseases and increasing demand for oxycodone drugs for treatment purposes is expected to contribute to the overall, market growth
Moreover, there has been an increase in investments in research on oxycodone drugs and a rise in the number of clinical trials focusing on oxycodone. For instance, in August 2022, the Third People's Hospital of Chengdu initiated a clinical trial in which the use of oxycodone for pain treatment after bariatric surgery was studied. Such clinical trials focusing on oxycodone drugs are expected to boost the growth of the studied market.
Therefore, due to the rising adoption of the oxycodon drugs for pain management and growing product developemnt, the studied market is anticipated to witness growth during the forecast period. However, the risk of complications associated with the drugs and stringent regulations on drug approval is anticipated to hinder the market growth over the forecast period.
Oxycodone Drugs Industry Segmentation
As per the scope of the report, oxycodone is an opioid medication used for the treatment of moderate to severe pain. These medications decrease the transmission of signals from the brain to the body parts. It comes under narcotic drugs and is a prescription medicine that is approved in combination with non-opioid medications. These drugs are available as short-acting or immediate-release (IR) and long-acting or prolonged-release (PR) formulations in various dosage forms. The oxycodone drugs market is segmented by product type (short-acting and long-acting), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| Product Type | |
| Short-acting | |
| Long-acting |
| Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Oxycodone Drugs Market Size Summary
The oxycodone drugs market is poised for significant growth over the forecast period, driven by an increasing prevalence of chronic pain conditions such as rheumatoid arthritis, cancer, and fibromyalgia. The COVID-19 pandemic initially disrupted the market due to supply chain challenges, but it also led to a rise in the use of oxycodone for pain management, as the drug's analgesic properties were beneficial during this period. The demand for oxycodone is further bolstered by its role as a preferred alternative to non-steroidal anti-inflammatory drugs (NSAIDs) for chronic pain management. The market is also experiencing a surge in research and clinical trials focused on oxycodone, which is expected to enhance its application and acceptance in pain management therapies.
North America is a dominant region in the oxycodone drugs market, largely due to the high incidence of cancer, rheumatoid arthritis, and osteoarthritis, which necessitate effective pain management solutions. The increasing burden of these conditions is driving the demand for oxycodone, as it is widely prescribed for managing severe pain. The market is moderately competitive, with major players like Sun Pharmaceutical Industries Ltd, Collegium Pharmaceutical Inc., and Endo Pharmaceuticals Inc. leading the charge. These companies are actively developing new formulations with reduced side effects, supported by favorable regulatory initiatives. The ongoing development and approval of abuse-deterrent formulations are expected to further propel market growth, offering new opportunities for oxycodone drugs in the coming years.
Oxycodone Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Investments in R&D and Clinical Trials by Key Players
-
1.2.2 Favorable Initiatives by FDA to Develop Abuse-Deterrent Formulations (ADFs)
-
-
1.3 Market Restraints
-
1.3.1 High Risk of Complications Associated with the Medication
-
1.3.2 Challenges in Development Stage and Stringent Regulatory Framework
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD Millions)
-
2.1 Product Type
-
2.1.1 Short-acting
-
2.1.2 Long-acting
-
-
2.2 Distribution Channel
-
2.2.1 Hospital Pharmacies
-
2.2.2 Retail Pharmacies
-
2.2.3 Online Pharmacies
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United states
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Oxycodone Drugs Market Size FAQs
What is the current Oxycodone Drugs Market size?
The Oxycodone Drugs Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Oxycodone Drugs Market?
Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Endo Pharmaceuticals Inc, Collegium Pharmaceutical Inc and Mallinckrodt Pharmaceuticals are the major companies operating in the Oxycodone Drugs Market.
